Literature DB >> 24889268

High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.

Jianguo Wen1, Hangwen Li, Wenjing Tao, Barbara Savoldo, Jessica A Foglesong, Lauren C King, Youli Zu, Chung-Che Chang.   

Abstract

Multiple myeloma (MM) stem cells, proposed to be responsible for the tumourigenesis, drug resistance and recurrence of this disease, are enriched in the cancer stem cell-like side population (SP). Cancer testis antigens (CTA) are attractive targets for immunotherapy because they are widely expressed in cancers but only in limited types of normal tissues. We designed a high throughput assay, which allowed simultaneous relative quantifying expression of 90 CTA genes associated with MM. In the three MM cell lines tested, six CTA genes were over-expressed in two and LUZP4 and ODF1 were universally up-regulated in all three cell lines. Subsequent study of primary bone marrow (BM) from eight MM patients and four healthy donors revealed that 19 CTA genes were up-regulated in SP of MM compared with mature plasma cells. In contrast, only two CTA genes showed a moderate increase in SP cells of healthy BM. Furthermore, knockdown using small interfering RNA (siRNA) revealed that LUZP4 expression is required for colony-forming ability and drug resistance in MM cells. Our findings indicate that multiple CTA have unique expression profiles in MM SP, suggesting that CTA may serve as targets for immunotherapy that it specific for MM stem cells and which may lead to the long-term cure of MM.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer testis antigen; high throughput; multiple myeloma; quantitative RT-PCR; side population

Mesh:

Substances:

Year:  2014        PMID: 24889268      PMCID: PMC4365818          DOI: 10.1111/bjh.12951

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  31 in total

1.  CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype.

Authors:  Teresa Paíno; Enrique M Ocio; Bruno Paiva; Laura San-Segundo; Mercedes Garayoa; Norma C Gutiérrez; M Eugenia Sarasquete; Atanasio Pandiella; Alberto Orfao; Jesús F San Miguel
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 2.  Cancer stem cells in multiple myeloma.

Authors:  Nilanjan Ghosh; William Matsui
Journal:  Cancer Lett       Date:  2008-09-21       Impact factor: 8.679

3.  Non-side-population hematopoietic stem cells in mouse bone marrow.

Authors:  Yohei Morita; Hideo Ema; Satoshi Yamazaki; Hiromitsu Nakauchi
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

4.  Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors.

Authors:  A Ikegame; S Ozaki; D Tsuji; T Harada; S Fujii; S Nakamura; H Miki; A Nakano; K Kagawa; K Takeuchi; M Abe; K Watanabe; M Hiasa; N Kimura; Y Kikuchi; A Sakamoto; K Habu; M Endo; K Itoh; H Yamada-Okabe; T Matsumoto
Journal:  Leukemia       Date:  2012-03-20       Impact factor: 11.528

5.  PCR assays detect B-lymphocyte clonality in formalin-fixed, paraffin-embedded specimens of classical hodgkin lymphoma without microdissection.

Authors:  W Richard Burack; Todd S Laughlin; Jonathan W Friedberg; Janice M Spence; Paul G Rothberg
Journal:  Am J Clin Pathol       Date:  2010-07       Impact factor: 2.493

6.  Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo.

Authors:  Jianguo Wen; Yongdong Feng; Chad C Bjorklund; Michael Wang; Robert Z Orlowski; Zheng-Zheng Shi; Bing Liao; Jacqueline O'Hare; Youli Zu; Andrew V Schally; Chung-Che Chang
Journal:  Mol Cancer Ther       Date:  2010-11-09       Impact factor: 6.261

7.  Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations.

Authors:  Amirtha Ganesh Dakshinamurthy; Rajkumar Ramesar; Paul Goldberg; Jonathan M Blackburn
Journal:  Biotechnol J       Date:  2008-11       Impact factor: 4.677

8.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

9.  Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.

Authors:  Jianguo Wen; Yongdong Feng; Wanting Huang; Haiyun Chen; Bing Liao; Lawrence Rice; Hector A Preti; Rammurti T Kamble; Youli Zu; Douglas J Ballon; Chung-Che Chang
Journal:  Leuk Res       Date:  2009-07-15       Impact factor: 3.156

10.  MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas.

Authors:  Chantal Mengus; Elke Schultz-Thater; Julie Coulot; Zeljko Kastelan; Eleonora Goluza; Marijana Coric; Giulio C Spagnoli; Tvrtko Hudolin
Journal:  Int J Cancer       Date:  2012-11-16       Impact factor: 7.396

View more
  5 in total

1.  Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.

Authors:  Jianguo Wen; Wenjing Tao; Isere Kuiatse; Pei Lin; Yongdong Feng; Richard J Jones; Robert Z Orlowski; Youli Zu
Journal:  Int J Cancer       Date:  2014-07-23       Impact factor: 7.396

2.  Involvement of X-chromosome Reactivation in Augmenting Cancer Testis Antigens Expression: A Hypothesis.

Authors:  Chang Liu; Bin Luo; Xiao-Xun Xie; Xing-Sheng Liao; Jun Fu; Ying-Ying Ge; Xi-Sheng Li; Gao-Shui Guo; Ning Shen; Shao-Wen Xiao; Qing-Mei Zhang
Journal:  Curr Med Sci       Date:  2018-03-15

3.  Luzp4 defines a new mRNA export pathway in cancer cells.

Authors:  Nicolas Viphakone; Marcus G Cumberbatch; Michaela J Livingstone; Paul R Heath; Mark J Dickman; James W Catto; Stuart A Wilson
Journal:  Nucleic Acids Res       Date:  2015-02-06       Impact factor: 16.971

Review 4.  Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?

Authors:  Reinaldo Franqui-Machin; Erik B Wendlandt; Siegfried Janz; Fenghuang Zhan; Guido Tricot
Journal:  Oncotarget       Date:  2015-12-01

5.  Identification of CD8+ T-cell epitope from multiple myeloma-specific antigen AKAP4.

Authors:  Ning Ma; Huihui Liu; Yang Zhang; Wei Liu; Zeyin Liang; Qian Wang; Yuhua Sun; Lihong Wang; Yuan Li; Hanyun Ren; Yujun Dong
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.